Prospective observational study on efficacy and safety of PEGASYS for the treatment of patients with HBeAg positive or HBeAg negative chronic active hepatitis B - Prospective observational study of PEGASYS for hepatitis B

The incidence of ADRs in the 536 patients in the safety analysis set was 47.76% (256/536 patients), with 565 events reported. By system organ class (SOC), the most common ADRs (5% incidence) in the 536 patients in the safety analysis set were investigations (28.92%, 155/536 patients), general disorders and administration site condition (12.31%, 66/536 patients), and skin and subcutaneous tissue disorders (9.33%, 50/536 patients.